Rethinking de novo immune hepatitis, an old concept for liver allograft rejection: Relevance of glutathione S-transferase T1 mismatch
|
摘要
Antibody-mediated rejection(AMR) in liver transplantation has long been underestimated. The concept of the liver as an organ susceptible to AMR has emerged in recent years, not only in the context of the major histocompatibility complex with the presence of HLA donor-specific antibodies, but also with antigens regarded as "minor", whose role in AMR has been demonstrated. Among them, antibodies against glutathione S-transferase T1 have been found in 100% of patients with de novo autoimmune hepatitis(dn AIH) when studied. In its latest update, the Banff Working Group for liver allograft pathology proposed replacing the term dn AIH with plasma cell(PC)-rich rejection. Antibodies to glutathione S-transferase T1(GSTT1) in null recipients of GSTT1 positive donors have been included as a contributory but nonessential feature of the diagnosis of PC-rich rejection. Also in this update, non-organ-specific anti-nuclear or smooth muscle autoantibodies are no longer included as diagnostic criteria. Although initially found in a proportion of patients with PC-rich rejection, the presence of autoantibodies is misleading since they are not diseasespecific and appear in many different contexts as bystanders. The cellular types and proportions of the inflammatory infiltrates in diagnostic biopsies have been studied in detail very recently. PC-rich rejection biopsies present a characteristic cellular profile with a predominance of T lymphocytes and a high proportion of PCs, close to 30%, of which 16.48% are Ig G4+. New data on the relevance of GSTT1-specific T lymphocytes to PC-rich rejection will be discussed in this review.
Antibody-mediated rejection(AMR) in liver transplantation has long been underestimated. The concept of the liver as an organ susceptible to AMR has emerged in recent years, not only in the context of the major histocompatibility complex with the presence of HLA donor-specific antibodies, but also with antigens regarded as "minor", whose role in AMR has been demonstrated. Among them, antibodies against glutathione S-transferase T1 have been found in 100% of patients with de novo autoimmune hepatitis(dn AIH) when studied. In its latest update, the Banff Working Group for liver allograft pathology proposed replacing the term dn AIH with plasma cell(PC)-rich rejection. Antibodies to glutathione S-transferase T1(GSTT1) in null recipients of GSTT1 positive donors have been included as a contributory but nonessential feature of the diagnosis of PC-rich rejection. Also in this update, non-organ-specific anti-nuclear or smooth muscle autoantibodies are no longer included as diagnostic criteria. Although initially found in a proportion of patients with PC-rich rejection, the presence of autoantibodies is misleading since they are not diseasespecific and appear in many different contexts as bystanders. The cellular types and proportions of the inflammatory infiltrates in diagnostic biopsies have been studied in detail very recently. PC-rich rejection biopsies present a characteristic cellular profile with a predominance of T lymphocytes and a high proportion of PCs, close to 30%, of which 16.48% are Ig G4+. New data on the relevance of GSTT1-specific T lymphocytes to PC-rich rejection will be discussed in this review.
Antibody-mediated rejection(AMR) in liver transplantation has long been underestimated. The concept of the liver as an organ susceptible to AMR has emerged in recent years, not only in the context of the major histocompatibility complex with the presence of HLA donor-specific antibodies, but also with antigens regarded as "minor", whose role in AMR has been demonstrated. Among them, antibodies against glutathione S-transferase T1 have been found in 100% of patients with de novo autoimmune hepatitis(dn AIH) when studied. In its latest update, the Banff Working Group for liver allograft pathology proposed replacing the term dn AIH with plasma cell(PC)-rich rejection. Antibodies to glutathione S-transferase T1(GSTT1) in null recipients of GSTT1 positive donors have been included as a contributory but nonessential feature of the diagnosis of PC-rich rejection. Also in this update, non-organ-specific anti-nuclear or smooth muscle autoantibodies are no longer included as diagnostic criteria. Although initially found in a proportion of patients with PC-rich rejection, the presence of autoantibodies is misleading since they are not diseasespecific and appear in many different contexts as bystanders. The cellular types and proportions of the inflammatory infiltrates in diagnostic biopsies have been studied in detail very recently. PC-rich rejection biopsies present a characteristic cellular profile with a predominance of T lymphocytes and a high proportion of PCs, close to 30%, of which 16.48% are Ig G4+. New data on the relevance of GSTT1-specific T lymphocytes to PC-rich rejection will be discussed in this review.
引文
1 Demetris AJ,Bellamy C,Hübscher Sg,O’Leary J,Randhawa PS,Feng S,Neil D,Colvin RB,Mc Caughan g,Fung JJ,Del Bello A,Reinholt FP,Haga H,Adeyi O,Czaja AJ,Schiano T,Fiel MI,Smith ML,Sebagh M,Tanigawa RY,Yilmaz F,Alexander g,Baiocchi L,Balasubramanian M,Batal I,Bhan AK,Bucuvalas J,Cerski CTS,Charlotte F,de Vera ME,El Monayeri M,Fontes P,Furth EE,gouw ASH,Hafezi-Bakhtiari S,Hart J,Honsova E,Ismail W,Itoh T,Jhala NC,Khettry U,Klintmalm g B,Knechtle S,Koshiba T,Kozlowski T,Lassman CR,Lerut J,Levitsky J,Licini L,Liotta R,Mazariegos g,Minervini MI,Misdraji J,Mohanakumar T,M?lne J,Nasser I,Neuberger J,O’Neil M,Pappo O,Petrovic L,Ruiz P,Sa?ol?,Sanchez Fueyo A,Sasatomi E,Shaked A,Shiller M,Shimizu T,Sis B,Sonzogni A,Stevenson HL,Thung SN,Tisone g,Tsamandas AC,Wernerson A,Wu T,Zeevi A,Zen Y.2016 Comprehensive Update of the Banff Working group on Liver Allograft Pathology:Introduction of Antibody-Mediated Rejection.Am J Transplant2016;16:2816-2835[PMID:27273869 DOI:10.1111/ajt.13909]
2 Kerkar N,Hadzi?N,Davies ET,Portmann B,Donaldson PT,Rela M,Heaton ND,Vergani D,Mieli-Vergani g.De-novo autoimmune hepatitis after liver transplantation.Lancet 1998;351:409-413[PMID:9482295 DOI:10.1016/S0140-6736(97)06478-7]
3 Gupta P,Hart J,Millis JM,Cronin D,Brady L.De novo hepatitis with autoimmune antibodies and atypical histology:a rare cause of late graft dysfunction after pediatric liver transplantation.Transplantation 2001;71:664-668[PMID:11292299]
4 Andries S,Casamayou L,Sempoux C,Burlet M,Reding R,Bernard Otte J,Buts JP,Sokal E.Posttransplant immune hepatitis in pediatric liver transplant recipients:incidence and maintenance therapy with azathioprine.Transplantation 2001;72:267-272[PMID:11477351]
5 Hernandez HM,Kovarik P,Whitington PF,Alonso EM.Autoimmune hepatitis as a late complication of liver transplantation.J Pediatr Gastroenterol Nutr 2001;32:131-136[PMID:11321380]
6 Petz W,Sonzogni A,Bertani A,Spada M,Lucianetti A,Colledan M,gridelli B.A cause of late graft dysfunction after pediatric liver transplantation:de novo autoimmune hepatitis.Transplant Proc 2002;34:1958-1959[PMID:12176643 DOI:10.1016/S0041-1345(02)03137-8]
7 Miyagawa-Hayashino A,Haga H,Sakurai T,Shirase T,Manabe T,Egawa H.De novo autoimmune hepatitis affecting allograft but not the native liver in auxiliary partial orthotopic liver transplantation.Transplantation 2003;76:271-272[PMID:12865828 DOI:10.1097/01.TP.0000072338.88465.59]
8 Gibelli NE,Tannuri U,Mello ES,Can?ado ER,Santos MM,Ayoub AA,Maksoud-Filho Jg,Velhote MC,Silva MM,Pinho-Apezzato ML,Maksoud Jg.Successful treatment of de novo autoimmune hepatitis and cirrhosis after pediatric liver transplantation.Pediatr Transplant 2006;10:371-376[PMID:16677364 DOI:10.1111/j.1399-3046.2005.00470.x]
9 Evans HM,Kelly DA,Mc Kiernan PJ,Hübscher S.Progressive histological damage in liver allografts following pediatric liver transplantation.Hepatology 2006;43:1109-1117[PMID:16628633DOI:10.1002/hep.21152]
10 Riva S,Sonzogni A,Bravi M,Bertani A,Alessio Mg,Candusso M,Stroppa P,Melzi ML,Spada M,gridelli B,Colledan M,Torre g.Late graft dysfunction and autoantibodies after liver transplantation in children:preliminary results of an Italian experience.Liver Transpl 2006;12:573-577[PMID:16555335 DOI:10.1002/lt.20673]
11 Oya H,Sato Y,Yamamoto S,Kobayashi T,Watanabe T,Kokai H,Hatakeyama K.De novo autoimmune hepatitis after living donor liver transplantation in a 25-day-old newborn baby:a case report.Transplant Proc 2009;41:433-434[PMID:19249573 DOI:10.1016/j.transproceed.2008.10.031]
12 Cho JM,Kim KM,Oh SH,Lee YJ,Rhee KW,Yu E.De novo autoimmune hepatitis in Korean children after liver transplantation:a single institution’s experience.Transplant Proc 2011;43:2394-2396[PMID:21839275 DOI:10.1016/j.transproceed.2011.05.030]
13 Pongpaibul A,Venick RS,Mc Diarmid SV,Lassman CR.Histopathology of de novo autoimmune hepatitis.Liver Transpl2012;18:811-818[PMID:22378542 DOI:10.1002/lt.23422]
14 Ekong UD,Mc Kiernan P,Martinez M,Lobritto S,Kelly D,Ng VL,Alonso EM,Avitzur Y.Long-term outcomes of de novo autoimmune hepatitis in pediatric liver transplant recipients.Pediatr Transplant 2017;21[PMID:28556542 DOI:10.1111/petr.12945]
15 Jones DE,James OF,Portmann B,Burt AD,Williams R,Hudson M.Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis.Hepatology 1999;30:53-57[PMID:10385638 DOI:10.1002/hep.510300103]
16 Heneghan MA,Portmann BC,Norris SM,Williams R,Muiesan P,Rela M,Heaton ND,O’grady Jg.graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults.Hepatology 2001;34:464-470[PMID:11526530 DOI:10.1053/jhep.2001.26756]
17 Salcedo M,Vaquero J,Ba?ares R,Rodríguez-Mahou M,Alvarez E,Vicario JL,Hernández-Albújar A,Tíscar JL,Rincón D,Alonso S,De Diego A,Clemente g.Response to steroids in de novo autoimmune hepatitis after liver transplantation.Hepatology 2002;35:349-356[PMID:11826408 DOI:10.1053/jhep.2002.31167]
18 Aguilera I,Sousa JM,gavilán F,Bernardos A,Wichmann I,Nu?ez-Roldán A.glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation.Liver Transpl 2004;10:1166-1172[PMID:15350010 DOI:10.1002/lt.20209]
19 Miyagawa-Hayashino A,Haga H,Egawa H,Hayashino Y,Sakurai T,Minamiguchi S,Tanaka K,Manabe T.Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation.Transplantation 2004;78:128-135[PMID:15257051]
20 Tsuji H,Hiramatsu K,Minato H,Kaneko S,Nakanuma Y.Auxiliary partial orthotopic liver transplantation with de novo autoimmune hepatitis in the allograft and leftover primary biliary cirrhosis in the native liver.Semin Liver Dis 2005;25:371-377[PMID:16143952 DOI:10.1055/s-2005-916328]
21 Rodríguez-Diaz Y,Reyes-Rodriguez R,Dorta-Francisco MC,Aguilera I,Perera-Molinero A,Moneva-Arce E,Aviles-Ruiz JF.De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis.Transplant Proc 2006;38:1467-1470[PMID:16797335 DOI:10.1016/j.transproceed.2006.03.071]
22 Yoshizawa K,Shirakawa H,Ichijo T,Umemura T,Tanaka E,Kiyosawa K,Imagawa E,Matsuda K,Hidaka E,Sano K,Nakazawa Y,Ikegami T,Hashikura Y,Miyagawa S,Ota M,Nakano M.De novo autoimmune hepatitis following livingdonor liver transplantation for primary biliary cirrhosis.Clin Transplant 2008;22:385-390[PMID:18190552 DOI:10.1111/j.1399-0012.2007.00787.x]
23 Fiel MI,Agarwal K,Stanca C,Elhajj N,Kontorinis N,Thung SN,Schiano TD.Posttransplant plasma cell hepatitis(de novo autoimmune hepatitis)is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus.Liver Transpl2008;14:861-871[PMID:18508382 DOI:10.1002/lt.21447]
24 Zhang Y,Wang B,Wang T.De novo autoimmune hepatitis with centrilobular necrosis following liver transplantation for primary biliary cirrhosis:a case report.Transplant Proc 2010;42:3854-3857[PMID:21094869 DOI:10.1016/j.transproceed.2010.08.062]
25 Montano-Loza AJ,Vargas-Vorackova F,Ma M,Bain Vg,Burak K,Kumar T,Mason AL.Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation.Liver Int 2012;32:1426-1433[PMID:22712495 DOI:10.1111/j.1478-3231.2012.02832.x]
26 Banff Working Group.,Demetris AJ,Adeyi O,Bellamy CO,Clouston A,Charlotte F,Czaja A,Daskal I,El-Monayeri MS,Fontes P,Fung J,gridelli B,guido M,Haga H,Hart J,Honsova E,Hubscher S,Itoh T,Jhala N,Jungmann P,Khettry U,Lassman C,Ligato S,Lunz Jg 3rd,Marcos A,Minervini MI,M?lne J,Nalesnik M,Nasser I,Neil D,Ochoa E,Pappo O,Randhawa P,Reinholt FP,Ruiz P,Sebagh M,Spada M,Sonzogni A,Tsamandas AC,Wernerson A,Wu T,Yilmaz F.Liver biopsy interpretation for causes of late liver allograft dysfunction.Hepatology 2006;44:489-501[PMID:16871565 DOI:10.1002/hep.21280]
27 Shaikh OS,Demetris AJ.Idiopathic posttransplantation hepatitis?Liver Transpl 2007;13:943-946[PMID:17600346 DOI:10.1002/lt.21202]
28 Schreuder TC,Hübscher Sg,Neuberger J.Autoimmune liver diseases and recurrence after orthotopic liver transplantation:what have we learned so far?Transpl Int 2009;22:144-152[PMID:18662365 DOI:10.1111/j.1432-2277.2008.00729]
29 Hübscher SG.Antibody-mediated rejection in the liver allograft.Curr Opin Organ Transplant 2012;17:280-286[PMID:22569512DOI:10.1097/MOT.0b013e328353584c]
30 Hübscher SG.What is the long-term outcome of the liver allograft?J Hepatol 2011;55:702-717[PMID:21426919 DOI:10.1016/j.jhep.2011.03.005]
31 Sebagh M,Castillo-Rama M,Azoulay D,Coilly A,Delvart V,Allard MA,Dos Santos A,Johanet C,Roque-Afonso AM,Saliba F,Duclos-Vallée JC,Samuel D,Demetris AJ.Histologic findings predictive of a diagnosis of de novo autoimmune hepatitis after liver transplantation in adults.Transplantation 2013;96:670-678[PMID:23982338 DOI:10.1097/TP.0b013e31829eda7f]
32 Vukotic R,Vitale g,D’Errico-grigioni A,Muratori L,Andreone P.De novo autoimmune hepatitis in liver transplant:State-of-theart review.World J Gastroenterol 2016;22:2906-2914[PMID:26973387 DOI:10.3748/wjg.v22.i10.2906]
33 Nagai S,Ito M,Kamei H,Nakamura T,Ando H,Kiuchi T.Indirect immunohistochemical evaluation of graft fibrosis and interface hepatitis after pediatric liver transplantation.Pediatr Transplant 2010;14:342-350[PMID:19744282 DOI:10.1111/j.1399-3046.2009.01234.x]
34 Demetris AJ,Sebagh M.Plasma cell hepatitis in liver allografts:Variant of rejection or autoimmune hepatitis?Liver Transpl 2008;14:750-755[PMID:18508366 DOI:10.1002/lt.21518]
35 Solez K,Colvin RB,Racusen LC,Haas M,Sis B,Mengel M,Halloran PF,Baldwin W,Banfi G,Collins AB,Cosio F,David DS,Drachenberg C,Einecke g,Fogo AB,gibson IW,glotz D,Iskandar SS,Kraus E,Lerut E,Mannon RB,Mihatsch M,Nankivell BJ,Nickeleit V,Papadimitriou JC,Randhawa P,Regele H,Renaudin K,Roberts I,Seron D,Smith RN,Valente M.Banff 07 classification of renal allograft pathology:updates and future directions.Am JTransplant 2008;8:753-760[PMID:18294345 DOI:10.1111/j.1600-6143.2008.02159.x]
36 Aguilera I,Sousa JM,gavilan F,gomez L,Alvarez-Márquez A,Nú?ez-Roldán A.Complement component 4d immunostaining in liver allografts of patients with de novo immune hepatitis.Liver Transpl 2011;17:779-788[PMID:21425430 DOI:10.1002/lt.22302]
37 Trivedi A,Schiano TD,Ward SC,Thung SN,Fiel MI,Levitsky J.C4d is present in portal venules in plasma cell hepatitis and may also be used as a predictor for its development.Hepatology 2014;60:457A
38 Deshpande V,Zen Y,Chan JK,Yi EE,Sato Y,Yoshino T,Kl?ppel g,Heathcote Jg,Khosroshahi A,Ferry JA,Aalberse RC,Bloch DB,Brugge WR,Bateman AC,Carruthers MN,Chari ST,Cheuk W,Cornell LD,Fernandez-Del Castillo C,Forcione Dg,Hamilos DL,Kamisawa T,Kasashima S,Kawa S,Kawano M,Lauwers g Y,Masaki Y,Nakanuma Y,Notohara K,Okazaki K,Ryu JK,Saeki T,Sahani DV,Smyrk TC,Stone JR,Takahira M,Webster g J,Yamamoto M,Zamboni g,Umehara H,Stone JH.Consensus statement on the pathology of Igg4-related disease.Mod Pathol 2012;25:1181-1192[PMID:22596100 DOI:10.1038/modpathol.2012.72]
39 Tamaro G,Sonzogni A,Torre g.Monitoring“de novo”autoimmune hepatitis(LKM positive)by serum type-IV collagen after liver transplant:a paediatric case.Clin Chim Acta 2001;310:25-29[PMID:11485751 DOI:10.1016/S0009-8981(01)00509-5]
40 Tripathi D,Neuberger J.Autoimmune hepatitis and liver transplantation:indications,results,and management of recurrent disease.Semin Liver Dis 2009;29:286-296[PMID:19676001DOI:10.1055/s-0029-1233531]
41 Wichmann I,Aguilera I,Sousa JM,Bernardos A,garcía Nú?ez EJ,Vigil E,Magari?o R,Magari?o I,Torres A,Nú?ez-Roldán A.Antibodies against glutathione S-transferase T1 in non-solid organ transplanted patients.Transfusion 2006;46:1505-1509[PMID:16965576 DOI:10.1111/j.1537-2995.2006.00938.x]
42 Aguilera I,Wichmann I,Sousa JM,Bernardos A,Franco E,garcía-Lozano JR,Nú?ez-Roldán A.Antibodies against glutathione S-transferase T1(g STT1)in patients with de novo immune hepatitis following liver transplantation.Clin Exp Immunol 2001;126:535-539[PMID:11737073]
43 Rodriguez-Mahou M,Salcedo M,Fernandez-Cruz E,Tiscar JL,Ba?ares R,Clemente g,Vicario JL,Alvarez E,Rodriguez-Sainz C.Antibodies against glutathione S-transferase T1(g STT1)in patients with g STT1 null genotype as prognostic marker:long-term followup after liver transplantation.Transplantation 2007;83:1126-1129[PMID:17452905 DOI:10.1097/01.tp.0000259963.47350.da]
44 Czaja AJ.Diagnosis,pathogenesis,and treatment of autoimmune hepatitis after liver transplantation.Dig Dis Sci 2012;57:2248-2266[PMID:22562533 DOI:10.1007/s10620-012-2179-3]
45 Bellamy CO.Complement C4d immunohistochemistry in the assessment of liver allograft biopsy samples:applications and pitfalls.Liver Transpl 2011;17:747-750[PMID:21542127]
46 Haga H,Egawa H,Fujimoto Y,Ueda M,Miyagawa-Hayashino A,Sakurai T,Okuno T,Koyanagi I,Takada Y,Manabe T.Acute humoral rejection and C4d immunostaining in ABO blood typeincompatible liver transplantation.Liver Transpl 2006;12:457-464[PMID:16498648 DOI:10.1002/lt.20652]
47 Kozlowski T,Rubinas T,Nickeleit V,Woosley J,Schmitz J,Collins D,Hayashi P,Passannante A,Andreoni K.Liver allograft antibodymediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies.Liver Transpl 2011;17:357-368[PMID:21445918 DOI:10.1002/lt.22233]
48 Dumortier J,Scoazec JY,guillaud O,Hequet O,Hervieu V,Boillot O.Treatment of severe refractory de novo auto-immune hepatitis after liver transplantation with plasmapheresis.Clin Res Hepatol Gastroenterol 2015;39:e83-e85[PMID:26070570 DOI:10.1016/j.clinre.2015.04.003]
49 Wozniak LJ,Hickey MJ,Venick RS,Vargas JH,Farmer Dg,Busuttil RW,Mc Diarmid SV,Reed EF.Donor-specific HLAAntibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation.Transplantation 2015;99:1416-1422[PMID:26038872 DOI:10.1097/TP.0000000000000796]
50 Ward SC,Schiano TD,Thung SN,Fiel MI.Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation:case-control study showing poor outcome and predictive features in the liver explant.Liver Transpl 2009;15:1826-1833[PMID:19938116DOI:10.1002/lt.21949]
51 Neuberger J.An update on liver transplantation:A critical review.J Autoimmun 2016;66:51-59[PMID:26350881 DOI:10.1016/j.jaut.2015.08.021]
52 Mack CL.What Causes Biliary Atresia?Unique Aspects of the Neonatal Immune System Provide Clues to Disease Pathogenesis.Cell Mol Gastroenterol Hepatol 2015;1:267-274[PMID:26090510 DOI:10.1016/j.jcmgh.2015.04.001]
53 Alvarez F.Is biliary atresia an immune mediated disease?JHepatol 2013;59:648-650[PMID:23792027 DOI:10.1016/j.jhep.2013.06.006]
54 Pang SY,Dai YM,Zhang RZ,Chen YH,Peng XF,Fu J,Chen ZR,Liu YF,Yang LY,Wen Z,Yu JK,Liu HY.Autoimmune liver disease-related autoantibodies in patients with biliary atresia.World J Gastroenterol 2018;24:387-396[PMID:29391761 DOI:10.3748/wjg.v24.i3.387]
55 Muraji T,Ohtani H,Ieiri S.Unique manifestations of biliary atresia provide new immunological insight into its etiopathogenesis.Pediatr Surg Int 2017;33:1249-1253[PMID:29022092 DOI:10.1007/s00383-017-4155-7]
56 Martínez-Bravo MJ,Sánchez B,Sousa JM,Acevedo MJ,gómezBravo MA,Nú?ez-Roldán A,Aguilera I.T-cell allorecognition of donor glutathione S-transferase T1 in plasma cell-rich rejection.World J Hepatol 2017;9:1115-1124[PMID:29026463 DOI:10.4254/wjh.v9.i27.1115]
57 Vergani D,Mieli-Vergani g.The impact of autoimmunity on hepatocytes.Semin Liver Dis 2007;27:140-151[PMID:17520514DOI:10.1055/s-2007-979467]
58 Aguado-Domínguez E,gómez L,Sousa JM,gómez-Bravo Má,Nú?ez-Roldán A,Aguilera I.Identification of the cellular components involved in de novo immune hepatitis:a quantitative immunohistochemical analysis.J Transl Med 2018;16:62[PMID:29534755 DOI:10.1186/s12967-018-1440-8]
59 Eguchi S,Takatsuki M,Hidaka M,Tajima Y,Zen Y,Nakanuma Y,Kanematsu T.De novo autoimmune hepatitis after living donor liver transplantation is unlikely to be related to immunoglobulin subtype 4-related immune disease.J Gastroenterol Hepatol2008;23:e165-e169[PMID:18505414DOI:1 0.1111/j.1440-1746.2008.05347.x]
60 Castillo-Rama M,Sebagh M,Sasatomi E,Randhawa P,Isse K,Salgarkar AD,Ruppert K,Humar A,Demetris AJ.“Plasma cell hepatitis”in liver allografts:identification and characterization of an Igg4-rich cohort.Am J Transplant 2013;13:2966-2977[PMID:24011021 DOI:10.1111/ajt.12413]
61 Aguilera I,Martinez-Bravo MJ,Sousa JM,Pozo-Borrego AJ,Nú?ez-Roldán A.Igg subclass profile among anti-glutathione S-transferase T1 antibodies in post-transplant de novo immune hepatitis.Clin Transplant 2016;30:210-217[PMID:26663521DOI:10.1111/ctr.12675]
62 Ekong UD,Mathew J,Melin-Aldana H,Wang D,Alonso EM.Successful resolution of inflammation and increased regulatory Tcells in sirolimus-treated post-transplant allograft hepatitis.Pediatr Transplant 2012;16:165-175[PMID:22360400 DOI:10.1111/j.1399-3046.2012.01648.x]
63 Edmunds C,Ekong UD.Autoimmune Liver Disease Post-Liver Transplantation:A Summary and Proposed Areas for Future Research.Transplantation 2016;100:515-524[PMID:26447505DOI:10.1097/TP.0000000000000922]
64 Martínez-Bravo MJ,Calderón-Cabrera C,Márquez-Malaver FJ,Rodríguez N,guijarro M,Espigado I,Nú?ez-Roldán A,PérezSimón JA,Aguilera I.Mismatch on glutathione S-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation.Biol Blood Marrow Transplant 2014;20:1356-1362[PMID:24844856 DOI:10.1016/j.bbmt.2014.05.008]
65 Aguado-Dominguez E,Sousa JM,Perez-Simon JA,Aguilera I.Clinical association of anti-glutathione S-transferase T1antibodies and de novo immune hepatitis after hematopoietic cell transplantation.Dig Liver Dis 2018;50:418-419[PMID:29409781DOI:10.1016/j.dld.2017.12.033]
66 Kerkar N,Yanni g.‘De novo’and‘recurrent’autoimmune hepatitis after liver transplantation:A comprehensive review.JAutoimmun 2016;66:17-24[PMID:26377632 DOI:10.1016/j.jaut.2015.08.017]
67 Arterbery AS,Osafo-Addo A,Avitzur Y,Ciarleglio M,Deng Y,Lobritto SJ,Martinez M,Hafler DA,Kleinewietfeld M,Ekong UD.Production of Proinflammatory Cytokines by Monocytes in Liver-Transplanted Recipients with De Novo Autoimmune Hepatitis Is Enhanced and Induces TH1-like Regulatory T Cells.JImmunol 2016;196:4040-4051[PMID:27183637 DOI:10.4049/jimmunol.150227]
68 Aguilera I,Sousa JM,Praena JM,gómez-Bravo MA,Nú?ezRoldan A.Choice of calcineurin inhibitor may influence the development of de novo immune hepatitis associated with anti-g STT1 antibodies after liver transplantation.Clin Transplant 2011;25:207-212[PMID:20236132 DOI:10.1111/j.1399-0012.2010.01221.x]
2 Kerkar N,Hadzi?N,Davies ET,Portmann B,Donaldson PT,Rela M,Heaton ND,Vergani D,Mieli-Vergani g.De-novo autoimmune hepatitis after liver transplantation.Lancet 1998;351:409-413[PMID:9482295 DOI:10.1016/S0140-6736(97)06478-7]
3 Gupta P,Hart J,Millis JM,Cronin D,Brady L.De novo hepatitis with autoimmune antibodies and atypical histology:a rare cause of late graft dysfunction after pediatric liver transplantation.Transplantation 2001;71:664-668[PMID:11292299]
4 Andries S,Casamayou L,Sempoux C,Burlet M,Reding R,Bernard Otte J,Buts JP,Sokal E.Posttransplant immune hepatitis in pediatric liver transplant recipients:incidence and maintenance therapy with azathioprine.Transplantation 2001;72:267-272[PMID:11477351]
5 Hernandez HM,Kovarik P,Whitington PF,Alonso EM.Autoimmune hepatitis as a late complication of liver transplantation.J Pediatr Gastroenterol Nutr 2001;32:131-136[PMID:11321380]
6 Petz W,Sonzogni A,Bertani A,Spada M,Lucianetti A,Colledan M,gridelli B.A cause of late graft dysfunction after pediatric liver transplantation:de novo autoimmune hepatitis.Transplant Proc 2002;34:1958-1959[PMID:12176643 DOI:10.1016/S0041-1345(02)03137-8]
7 Miyagawa-Hayashino A,Haga H,Sakurai T,Shirase T,Manabe T,Egawa H.De novo autoimmune hepatitis affecting allograft but not the native liver in auxiliary partial orthotopic liver transplantation.Transplantation 2003;76:271-272[PMID:12865828 DOI:10.1097/01.TP.0000072338.88465.59]
8 Gibelli NE,Tannuri U,Mello ES,Can?ado ER,Santos MM,Ayoub AA,Maksoud-Filho Jg,Velhote MC,Silva MM,Pinho-Apezzato ML,Maksoud Jg.Successful treatment of de novo autoimmune hepatitis and cirrhosis after pediatric liver transplantation.Pediatr Transplant 2006;10:371-376[PMID:16677364 DOI:10.1111/j.1399-3046.2005.00470.x]
9 Evans HM,Kelly DA,Mc Kiernan PJ,Hübscher S.Progressive histological damage in liver allografts following pediatric liver transplantation.Hepatology 2006;43:1109-1117[PMID:16628633DOI:10.1002/hep.21152]
10 Riva S,Sonzogni A,Bravi M,Bertani A,Alessio Mg,Candusso M,Stroppa P,Melzi ML,Spada M,gridelli B,Colledan M,Torre g.Late graft dysfunction and autoantibodies after liver transplantation in children:preliminary results of an Italian experience.Liver Transpl 2006;12:573-577[PMID:16555335 DOI:10.1002/lt.20673]
11 Oya H,Sato Y,Yamamoto S,Kobayashi T,Watanabe T,Kokai H,Hatakeyama K.De novo autoimmune hepatitis after living donor liver transplantation in a 25-day-old newborn baby:a case report.Transplant Proc 2009;41:433-434[PMID:19249573 DOI:10.1016/j.transproceed.2008.10.031]
12 Cho JM,Kim KM,Oh SH,Lee YJ,Rhee KW,Yu E.De novo autoimmune hepatitis in Korean children after liver transplantation:a single institution’s experience.Transplant Proc 2011;43:2394-2396[PMID:21839275 DOI:10.1016/j.transproceed.2011.05.030]
13 Pongpaibul A,Venick RS,Mc Diarmid SV,Lassman CR.Histopathology of de novo autoimmune hepatitis.Liver Transpl2012;18:811-818[PMID:22378542 DOI:10.1002/lt.23422]
14 Ekong UD,Mc Kiernan P,Martinez M,Lobritto S,Kelly D,Ng VL,Alonso EM,Avitzur Y.Long-term outcomes of de novo autoimmune hepatitis in pediatric liver transplant recipients.Pediatr Transplant 2017;21[PMID:28556542 DOI:10.1111/petr.12945]
15 Jones DE,James OF,Portmann B,Burt AD,Williams R,Hudson M.Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis.Hepatology 1999;30:53-57[PMID:10385638 DOI:10.1002/hep.510300103]
16 Heneghan MA,Portmann BC,Norris SM,Williams R,Muiesan P,Rela M,Heaton ND,O’grady Jg.graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults.Hepatology 2001;34:464-470[PMID:11526530 DOI:10.1053/jhep.2001.26756]
17 Salcedo M,Vaquero J,Ba?ares R,Rodríguez-Mahou M,Alvarez E,Vicario JL,Hernández-Albújar A,Tíscar JL,Rincón D,Alonso S,De Diego A,Clemente g.Response to steroids in de novo autoimmune hepatitis after liver transplantation.Hepatology 2002;35:349-356[PMID:11826408 DOI:10.1053/jhep.2002.31167]
18 Aguilera I,Sousa JM,gavilán F,Bernardos A,Wichmann I,Nu?ez-Roldán A.glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation.Liver Transpl 2004;10:1166-1172[PMID:15350010 DOI:10.1002/lt.20209]
19 Miyagawa-Hayashino A,Haga H,Egawa H,Hayashino Y,Sakurai T,Minamiguchi S,Tanaka K,Manabe T.Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation.Transplantation 2004;78:128-135[PMID:15257051]
20 Tsuji H,Hiramatsu K,Minato H,Kaneko S,Nakanuma Y.Auxiliary partial orthotopic liver transplantation with de novo autoimmune hepatitis in the allograft and leftover primary biliary cirrhosis in the native liver.Semin Liver Dis 2005;25:371-377[PMID:16143952 DOI:10.1055/s-2005-916328]
21 Rodríguez-Diaz Y,Reyes-Rodriguez R,Dorta-Francisco MC,Aguilera I,Perera-Molinero A,Moneva-Arce E,Aviles-Ruiz JF.De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis.Transplant Proc 2006;38:1467-1470[PMID:16797335 DOI:10.1016/j.transproceed.2006.03.071]
22 Yoshizawa K,Shirakawa H,Ichijo T,Umemura T,Tanaka E,Kiyosawa K,Imagawa E,Matsuda K,Hidaka E,Sano K,Nakazawa Y,Ikegami T,Hashikura Y,Miyagawa S,Ota M,Nakano M.De novo autoimmune hepatitis following livingdonor liver transplantation for primary biliary cirrhosis.Clin Transplant 2008;22:385-390[PMID:18190552 DOI:10.1111/j.1399-0012.2007.00787.x]
23 Fiel MI,Agarwal K,Stanca C,Elhajj N,Kontorinis N,Thung SN,Schiano TD.Posttransplant plasma cell hepatitis(de novo autoimmune hepatitis)is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus.Liver Transpl2008;14:861-871[PMID:18508382 DOI:10.1002/lt.21447]
24 Zhang Y,Wang B,Wang T.De novo autoimmune hepatitis with centrilobular necrosis following liver transplantation for primary biliary cirrhosis:a case report.Transplant Proc 2010;42:3854-3857[PMID:21094869 DOI:10.1016/j.transproceed.2010.08.062]
25 Montano-Loza AJ,Vargas-Vorackova F,Ma M,Bain Vg,Burak K,Kumar T,Mason AL.Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation.Liver Int 2012;32:1426-1433[PMID:22712495 DOI:10.1111/j.1478-3231.2012.02832.x]
26 Banff Working Group.,Demetris AJ,Adeyi O,Bellamy CO,Clouston A,Charlotte F,Czaja A,Daskal I,El-Monayeri MS,Fontes P,Fung J,gridelli B,guido M,Haga H,Hart J,Honsova E,Hubscher S,Itoh T,Jhala N,Jungmann P,Khettry U,Lassman C,Ligato S,Lunz Jg 3rd,Marcos A,Minervini MI,M?lne J,Nalesnik M,Nasser I,Neil D,Ochoa E,Pappo O,Randhawa P,Reinholt FP,Ruiz P,Sebagh M,Spada M,Sonzogni A,Tsamandas AC,Wernerson A,Wu T,Yilmaz F.Liver biopsy interpretation for causes of late liver allograft dysfunction.Hepatology 2006;44:489-501[PMID:16871565 DOI:10.1002/hep.21280]
27 Shaikh OS,Demetris AJ.Idiopathic posttransplantation hepatitis?Liver Transpl 2007;13:943-946[PMID:17600346 DOI:10.1002/lt.21202]
28 Schreuder TC,Hübscher Sg,Neuberger J.Autoimmune liver diseases and recurrence after orthotopic liver transplantation:what have we learned so far?Transpl Int 2009;22:144-152[PMID:18662365 DOI:10.1111/j.1432-2277.2008.00729]
29 Hübscher SG.Antibody-mediated rejection in the liver allograft.Curr Opin Organ Transplant 2012;17:280-286[PMID:22569512DOI:10.1097/MOT.0b013e328353584c]
30 Hübscher SG.What is the long-term outcome of the liver allograft?J Hepatol 2011;55:702-717[PMID:21426919 DOI:10.1016/j.jhep.2011.03.005]
31 Sebagh M,Castillo-Rama M,Azoulay D,Coilly A,Delvart V,Allard MA,Dos Santos A,Johanet C,Roque-Afonso AM,Saliba F,Duclos-Vallée JC,Samuel D,Demetris AJ.Histologic findings predictive of a diagnosis of de novo autoimmune hepatitis after liver transplantation in adults.Transplantation 2013;96:670-678[PMID:23982338 DOI:10.1097/TP.0b013e31829eda7f]
32 Vukotic R,Vitale g,D’Errico-grigioni A,Muratori L,Andreone P.De novo autoimmune hepatitis in liver transplant:State-of-theart review.World J Gastroenterol 2016;22:2906-2914[PMID:26973387 DOI:10.3748/wjg.v22.i10.2906]
33 Nagai S,Ito M,Kamei H,Nakamura T,Ando H,Kiuchi T.Indirect immunohistochemical evaluation of graft fibrosis and interface hepatitis after pediatric liver transplantation.Pediatr Transplant 2010;14:342-350[PMID:19744282 DOI:10.1111/j.1399-3046.2009.01234.x]
34 Demetris AJ,Sebagh M.Plasma cell hepatitis in liver allografts:Variant of rejection or autoimmune hepatitis?Liver Transpl 2008;14:750-755[PMID:18508366 DOI:10.1002/lt.21518]
35 Solez K,Colvin RB,Racusen LC,Haas M,Sis B,Mengel M,Halloran PF,Baldwin W,Banfi G,Collins AB,Cosio F,David DS,Drachenberg C,Einecke g,Fogo AB,gibson IW,glotz D,Iskandar SS,Kraus E,Lerut E,Mannon RB,Mihatsch M,Nankivell BJ,Nickeleit V,Papadimitriou JC,Randhawa P,Regele H,Renaudin K,Roberts I,Seron D,Smith RN,Valente M.Banff 07 classification of renal allograft pathology:updates and future directions.Am JTransplant 2008;8:753-760[PMID:18294345 DOI:10.1111/j.1600-6143.2008.02159.x]
36 Aguilera I,Sousa JM,gavilan F,gomez L,Alvarez-Márquez A,Nú?ez-Roldán A.Complement component 4d immunostaining in liver allografts of patients with de novo immune hepatitis.Liver Transpl 2011;17:779-788[PMID:21425430 DOI:10.1002/lt.22302]
37 Trivedi A,Schiano TD,Ward SC,Thung SN,Fiel MI,Levitsky J.C4d is present in portal venules in plasma cell hepatitis and may also be used as a predictor for its development.Hepatology 2014;60:457A
38 Deshpande V,Zen Y,Chan JK,Yi EE,Sato Y,Yoshino T,Kl?ppel g,Heathcote Jg,Khosroshahi A,Ferry JA,Aalberse RC,Bloch DB,Brugge WR,Bateman AC,Carruthers MN,Chari ST,Cheuk W,Cornell LD,Fernandez-Del Castillo C,Forcione Dg,Hamilos DL,Kamisawa T,Kasashima S,Kawa S,Kawano M,Lauwers g Y,Masaki Y,Nakanuma Y,Notohara K,Okazaki K,Ryu JK,Saeki T,Sahani DV,Smyrk TC,Stone JR,Takahira M,Webster g J,Yamamoto M,Zamboni g,Umehara H,Stone JH.Consensus statement on the pathology of Igg4-related disease.Mod Pathol 2012;25:1181-1192[PMID:22596100 DOI:10.1038/modpathol.2012.72]
39 Tamaro G,Sonzogni A,Torre g.Monitoring“de novo”autoimmune hepatitis(LKM positive)by serum type-IV collagen after liver transplant:a paediatric case.Clin Chim Acta 2001;310:25-29[PMID:11485751 DOI:10.1016/S0009-8981(01)00509-5]
40 Tripathi D,Neuberger J.Autoimmune hepatitis and liver transplantation:indications,results,and management of recurrent disease.Semin Liver Dis 2009;29:286-296[PMID:19676001DOI:10.1055/s-0029-1233531]
41 Wichmann I,Aguilera I,Sousa JM,Bernardos A,garcía Nú?ez EJ,Vigil E,Magari?o R,Magari?o I,Torres A,Nú?ez-Roldán A.Antibodies against glutathione S-transferase T1 in non-solid organ transplanted patients.Transfusion 2006;46:1505-1509[PMID:16965576 DOI:10.1111/j.1537-2995.2006.00938.x]
42 Aguilera I,Wichmann I,Sousa JM,Bernardos A,Franco E,garcía-Lozano JR,Nú?ez-Roldán A.Antibodies against glutathione S-transferase T1(g STT1)in patients with de novo immune hepatitis following liver transplantation.Clin Exp Immunol 2001;126:535-539[PMID:11737073]
43 Rodriguez-Mahou M,Salcedo M,Fernandez-Cruz E,Tiscar JL,Ba?ares R,Clemente g,Vicario JL,Alvarez E,Rodriguez-Sainz C.Antibodies against glutathione S-transferase T1(g STT1)in patients with g STT1 null genotype as prognostic marker:long-term followup after liver transplantation.Transplantation 2007;83:1126-1129[PMID:17452905 DOI:10.1097/01.tp.0000259963.47350.da]
44 Czaja AJ.Diagnosis,pathogenesis,and treatment of autoimmune hepatitis after liver transplantation.Dig Dis Sci 2012;57:2248-2266[PMID:22562533 DOI:10.1007/s10620-012-2179-3]
45 Bellamy CO.Complement C4d immunohistochemistry in the assessment of liver allograft biopsy samples:applications and pitfalls.Liver Transpl 2011;17:747-750[PMID:21542127]
46 Haga H,Egawa H,Fujimoto Y,Ueda M,Miyagawa-Hayashino A,Sakurai T,Okuno T,Koyanagi I,Takada Y,Manabe T.Acute humoral rejection and C4d immunostaining in ABO blood typeincompatible liver transplantation.Liver Transpl 2006;12:457-464[PMID:16498648 DOI:10.1002/lt.20652]
47 Kozlowski T,Rubinas T,Nickeleit V,Woosley J,Schmitz J,Collins D,Hayashi P,Passannante A,Andreoni K.Liver allograft antibodymediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies.Liver Transpl 2011;17:357-368[PMID:21445918 DOI:10.1002/lt.22233]
48 Dumortier J,Scoazec JY,guillaud O,Hequet O,Hervieu V,Boillot O.Treatment of severe refractory de novo auto-immune hepatitis after liver transplantation with plasmapheresis.Clin Res Hepatol Gastroenterol 2015;39:e83-e85[PMID:26070570 DOI:10.1016/j.clinre.2015.04.003]
49 Wozniak LJ,Hickey MJ,Venick RS,Vargas JH,Farmer Dg,Busuttil RW,Mc Diarmid SV,Reed EF.Donor-specific HLAAntibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation.Transplantation 2015;99:1416-1422[PMID:26038872 DOI:10.1097/TP.0000000000000796]
50 Ward SC,Schiano TD,Thung SN,Fiel MI.Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation:case-control study showing poor outcome and predictive features in the liver explant.Liver Transpl 2009;15:1826-1833[PMID:19938116DOI:10.1002/lt.21949]
51 Neuberger J.An update on liver transplantation:A critical review.J Autoimmun 2016;66:51-59[PMID:26350881 DOI:10.1016/j.jaut.2015.08.021]
52 Mack CL.What Causes Biliary Atresia?Unique Aspects of the Neonatal Immune System Provide Clues to Disease Pathogenesis.Cell Mol Gastroenterol Hepatol 2015;1:267-274[PMID:26090510 DOI:10.1016/j.jcmgh.2015.04.001]
53 Alvarez F.Is biliary atresia an immune mediated disease?JHepatol 2013;59:648-650[PMID:23792027 DOI:10.1016/j.jhep.2013.06.006]
54 Pang SY,Dai YM,Zhang RZ,Chen YH,Peng XF,Fu J,Chen ZR,Liu YF,Yang LY,Wen Z,Yu JK,Liu HY.Autoimmune liver disease-related autoantibodies in patients with biliary atresia.World J Gastroenterol 2018;24:387-396[PMID:29391761 DOI:10.3748/wjg.v24.i3.387]
55 Muraji T,Ohtani H,Ieiri S.Unique manifestations of biliary atresia provide new immunological insight into its etiopathogenesis.Pediatr Surg Int 2017;33:1249-1253[PMID:29022092 DOI:10.1007/s00383-017-4155-7]
56 Martínez-Bravo MJ,Sánchez B,Sousa JM,Acevedo MJ,gómezBravo MA,Nú?ez-Roldán A,Aguilera I.T-cell allorecognition of donor glutathione S-transferase T1 in plasma cell-rich rejection.World J Hepatol 2017;9:1115-1124[PMID:29026463 DOI:10.4254/wjh.v9.i27.1115]
57 Vergani D,Mieli-Vergani g.The impact of autoimmunity on hepatocytes.Semin Liver Dis 2007;27:140-151[PMID:17520514DOI:10.1055/s-2007-979467]
58 Aguado-Domínguez E,gómez L,Sousa JM,gómez-Bravo Má,Nú?ez-Roldán A,Aguilera I.Identification of the cellular components involved in de novo immune hepatitis:a quantitative immunohistochemical analysis.J Transl Med 2018;16:62[PMID:29534755 DOI:10.1186/s12967-018-1440-8]
59 Eguchi S,Takatsuki M,Hidaka M,Tajima Y,Zen Y,Nakanuma Y,Kanematsu T.De novo autoimmune hepatitis after living donor liver transplantation is unlikely to be related to immunoglobulin subtype 4-related immune disease.J Gastroenterol Hepatol2008;23:e165-e169[PMID:18505414DOI:1 0.1111/j.1440-1746.2008.05347.x]
60 Castillo-Rama M,Sebagh M,Sasatomi E,Randhawa P,Isse K,Salgarkar AD,Ruppert K,Humar A,Demetris AJ.“Plasma cell hepatitis”in liver allografts:identification and characterization of an Igg4-rich cohort.Am J Transplant 2013;13:2966-2977[PMID:24011021 DOI:10.1111/ajt.12413]
61 Aguilera I,Martinez-Bravo MJ,Sousa JM,Pozo-Borrego AJ,Nú?ez-Roldán A.Igg subclass profile among anti-glutathione S-transferase T1 antibodies in post-transplant de novo immune hepatitis.Clin Transplant 2016;30:210-217[PMID:26663521DOI:10.1111/ctr.12675]
62 Ekong UD,Mathew J,Melin-Aldana H,Wang D,Alonso EM.Successful resolution of inflammation and increased regulatory Tcells in sirolimus-treated post-transplant allograft hepatitis.Pediatr Transplant 2012;16:165-175[PMID:22360400 DOI:10.1111/j.1399-3046.2012.01648.x]
63 Edmunds C,Ekong UD.Autoimmune Liver Disease Post-Liver Transplantation:A Summary and Proposed Areas for Future Research.Transplantation 2016;100:515-524[PMID:26447505DOI:10.1097/TP.0000000000000922]
64 Martínez-Bravo MJ,Calderón-Cabrera C,Márquez-Malaver FJ,Rodríguez N,guijarro M,Espigado I,Nú?ez-Roldán A,PérezSimón JA,Aguilera I.Mismatch on glutathione S-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation.Biol Blood Marrow Transplant 2014;20:1356-1362[PMID:24844856 DOI:10.1016/j.bbmt.2014.05.008]
65 Aguado-Dominguez E,Sousa JM,Perez-Simon JA,Aguilera I.Clinical association of anti-glutathione S-transferase T1antibodies and de novo immune hepatitis after hematopoietic cell transplantation.Dig Liver Dis 2018;50:418-419[PMID:29409781DOI:10.1016/j.dld.2017.12.033]
66 Kerkar N,Yanni g.‘De novo’and‘recurrent’autoimmune hepatitis after liver transplantation:A comprehensive review.JAutoimmun 2016;66:17-24[PMID:26377632 DOI:10.1016/j.jaut.2015.08.017]
67 Arterbery AS,Osafo-Addo A,Avitzur Y,Ciarleglio M,Deng Y,Lobritto SJ,Martinez M,Hafler DA,Kleinewietfeld M,Ekong UD.Production of Proinflammatory Cytokines by Monocytes in Liver-Transplanted Recipients with De Novo Autoimmune Hepatitis Is Enhanced and Induces TH1-like Regulatory T Cells.JImmunol 2016;196:4040-4051[PMID:27183637 DOI:10.4049/jimmunol.150227]
68 Aguilera I,Sousa JM,Praena JM,gómez-Bravo MA,Nú?ezRoldan A.Choice of calcineurin inhibitor may influence the development of de novo immune hepatitis associated with anti-g STT1 antibodies after liver transplantation.Clin Transplant 2011;25:207-212[PMID:20236132 DOI:10.1111/j.1399-0012.2010.01221.x]